Startup Deep Dive : Anthem Biosciences — the Rs 3,395 crore IPO that raised nothing for the company

Anthem Biosciences raised ₹3,395 crore (about $354 million at $1 ≈ ₹96.0) in one of 2025’s most heavily bid pharma IPOs — and not a single rupee of it reached the company. Every share on offer was an existing shareholder cashing out. The stock still listed at a 26.85% premium on 21 July 2025, and by September 2026 the Bengaluru contract-research firm was worth close to ₹49,000 crore.

That contradiction — a red-hot listing that raised nothing for the business — is the tell. Anthem does not need the money. It is a rare Indian pharma-services company that has grown for nearly two decades on its own cash, posts operating margins north of 40%, and quietly makes molecules for global drug firms that would rather not talk about who makes their chemistry. This is how a company started by three ex-Biocon executives became India’s most profitable listed CRDMO.

Quick facts

What Anthem does

Anthem is a CRDMO — a contract research, development and manufacturing organisation. In plain terms, global pharmaceutical and biotech companies hire Anthem to discover, develop and then physically make the chemistry behind their drugs, from a gram in a lab to tonnes in a plant. Anthem does not sell its own branded medicines. It sells the science and the manufacturing that sit behind other companies’ medicines, and it earns a fee for doing so. Its second, smaller business sells specialty ingredients it makes through fermentation — probiotics, enzymes, peptides, nutritional actives and niche generic APIs — often to the same kind of customers.

The origin

The founding insight was cost arbitrage with credibility. In the mid-2000s, Ajay Bhardwaj had watched India’s contract-research industry take shape from the inside. He began his career at Max India, then joined Biocon as one of its early employees, rising to President of Marketing and helping push the company into life sciences and contract research. He had seen, up close, that Western drug firms would pay well to move chemistry to a cheaper base — if the partner could be trusted with quality and secrecy.

In 2006 he left to build that partner himself. He brought two Biocon and Syngene colleagues who supplied what he lacked: Dr Ganesh Sambasivam, a chemist who became chief scientific officer, and K Ravindra Chandrappa, who took charge of manufacturing. Work began at a site in Bommasandra, Bengaluru, in January 2007, and the company raised its first customer invoice in July 2007. The bet was that a fermentation-and-synthesis house in India could offer Western pharma a “China alternative” — the same cost advantage, but with English-language science, respect for intellectual property, and regulator-grade quality. Nearly two decades on, that is exactly the pitch the company still makes.

The struggle years

Anthem’s hard years were not dramatic collapses; they were the slow, unglamorous grind of building trust in a business where a customer is handing you the recipe for a molecule it may spend a billion dollars commercialising. Two things made the early climb steep.

• No outside capital for over a decade. The founders funded growth from operations rather than venture money. That kept them in control but capped how fast they could add capacity, and it meant every new plant had to be earned from cash the business generated.
• Selling secrecy to sceptics. Big pharma does not casually move a proprietary process to a young Indian vendor. Anthem had to pass repeated client audits — it now undergoes more than 40 a year — and build accreditations (USFDA, ANVISA of Brazil, TGA of Australia, PMDA of Japan) before large customers would trust it with commercial-scale work.

The strategic pivot that shaped the company was choosing hard chemistry over easy volume. Rather than compete purely on low-cost generic APIs, Anthem invested in fermentation and in newer, harder-to-make modalities — peptides, oligonucleotides, lipids, antibody-drug conjugate components, flow chemistry and biotransformation. Those are areas with fewer credible suppliers and fatter margins, and they are the reason Anthem’s profitability looks unusual for an Indian pharma-services firm.

The turning point

The single turning-point event was the arrival of institutional capital in 2021, which converted a founder-run specialist into an IPO-ready platform. In January 2021, private equity firm True North bought roughly a 10% stake for about ₹617.7 crore, validating the business at scale for the first time and setting a valuation marker. On one side of that event was a self-funded company known mainly to its customers; on the other was a company with a professional cap table, an expansion plan and a clear path to the public markets.

The pay-off came four years later. When Anthem listed on 21 July 2025, the ₹3,395 crore offer for sale let True North and some promoters realise their gains, the shares opened at ₹723.05 on the NSE against the ₹570 issue price — a 26.85% premium — and the company carried a market capitalisation of roughly ₹40,716 crore on debut. The business that had taken 14 years to reach its first outside investor took barely four more to become one of India’s most valuable listed CRDMOs.

The money behind it

Anthem’s funding story is short because the company barely needed funding. The important facts:

• Bootstrapped for its first decade-plus. The founders grew the company on internal cash flow rather than successive venture rounds — unusual for a capital-hungry manufacturing business.
• True North, January 2021: the PE firm acquired about a 10% minority stake for roughly ₹617.7 crore, Anthem’s first major external investment and its pre-IPO validation.
• IPO, July 2025 — ₹3,395 crore, 100% offer for sale. Because it was entirely an OFS, the money went to selling shareholders (True North and promoters), not into the company. Anthem raised no fresh capital because it did not need to.
• Promoter control retained: the promoter group held above 74% after listing, so the founders still run the company they built.
• Net cash, not net debt: the company reported a net cash position of about ₹1,375 crore as of 31 March 2026 — funding its capacity expansion from its own balance sheet.

How it makes money

Anthem earns fees along the full life of a drug molecule, which is what “CRDMO” is meant to capture. The money comes in through two engines:

• CRDMO services (the core): customers pay for discovery and research (the “R&D” slice) and, far more lucratively, for developing and then manufacturing the molecule at scale (the “D&M” slice). Early research work is small-ticket but sticky; once Anthem is embedded in a molecule’s chemistry, the manufacturing revenue that follows can run for years.
• Specialty Ingredients (the products business): Anthem makes and sells fermentation-based products — probiotics, enzymes, peptides, nutritional actives, biosimilars and select generic APIs — as its own catalogue rather than as bespoke client work.

Where the margin sits is the part outsiders get wrong. The assumption is that Indian contract manufacturing is a thin-margin, high-volume game. Anthem’s is not: its operating margins have run in the high-30s to low-40s percent, because it leans on complex fermentation and new modalities where few suppliers can compete, rather than commodity synthesis where everyone can. The cost base is dominated by raw materials and specialised chemicals, plus scientific talent (over 1,500 employees) and the fixed cost of running cGMP-grade plants. The commercial catch is customer stickiness cutting both ways: it takes years to win a molecule, but once won, the switching cost for the customer is high — which is exactly why concentration is both Anthem’s strength and its risk.

The numbers

Four years of audited and reported consolidated results (₹ crore) show steady growth with rare-for-the-sector profitability:

The details behind the table:

• FY26 revenue: ₹2,124 crore, up about 15% over FY25’s ₹1,845 crore (Screener consolidated data; company FY26 results).
• FY26 profit after tax: ₹592 crore, up 31% year on year, with a PAT margin around 26% (company FY26 results).
• FY26 EBITDA: about ₹990 crore, a margin of 43.4% (company FY26 results) — the standout figure for an Indian pharma-services firm.
• Q4 FY26 revenue: ₹611 crore, up 26% year on year; Q4 PAT ₹190 crore at a 28.7% margin (company Q4 FY26 results).
• FY24’s dip in profit (₹367 crore, below FY23’s ₹385 crore) even as revenue rose shows margin pressure that year; profit recovered strongly in FY25 and FY26.

Where the money comes from

The revenue mix explains both the quality of the business and its exposure. In FY25:

• CRDMO was 81.65% of revenue — split into Development & Manufacturing at 70.78% and Research & Development at 10.87% (company data / IPO disclosures).
• Specialty Ingredients was the remaining 18.35% of revenue.
• Exports dominate: Europe contributed 56.61% and North America 26.42% of FY25 revenue — over 80% from the world’s two largest, most demanding pharma markets.
• Customer mix: large pharma is roughly half of revenue, emerging biotech about 20%, and mid-sized pharma around 10%, per IPO-period disclosures.

The surprise is the concentration underneath the growth: Anthem’s top five customers accounted for 70.92% of revenue from operations in FY25. The company that looks like a diversified services platform actually leans heavily on a handful of relationships — a structure that has powered the margins and is also the clearest thing that could go wrong.

The risks

These are drawn from the company’s own IPO disclosures, which is where the sharpest risks usually sit.

• Customer concentration. With the top five customers at 70.92% of FY25 revenue from operations, the loss, insourcing or pipeline failure of even one major account could materially dent revenue and cash flow. This is the single most-cited risk.
• Supply-chain dependence on China. Procurement from overseas suppliers rose from 24.60% of purchases in FY24 to 48.41% in FY25, driven largely by a single China-based supplier that accounted for about 26.78% of total material costs. A trade shock, tariff or geopolitical disruption there would hit input costs and continuity — ironic for a company that markets itself as a China alternative.
• Unhedged currency exposure. With over 80% of revenue from Europe and North America and no foreign-currency hedging in the three fiscal years before the IPO, a sharp move in the rupee, euro or dollar flows straight to reported earnings.
• Regulatory and competitive pressure. Any adverse inspection outcome from the USFDA, PMDA, ANVISA or TGA could stall commercial supply, and Anthem competes for the same work as global heavyweights such as WuXi AppTec, Lonza and domestic peer Syngene.

The takeaway

The transferable lesson from Anthem is that patience plus difficulty is a moat. The founders spent over a decade refusing outside money and choosing the hardest chemistry — fermentation, peptides, new modalities — precisely because it was hard to copy. That combination bought them pricing power most Indian manufacturers never get, and it let them go public on their own terms, raising nothing while their early backer cashed out at a 26.85% listing premium. The uncomfortable flip side is written into the same story: the customers who made those margins possible are few, and the supply chain that feeds them still runs partly through the country Anthem was built to replace. High-quality businesses and concentrated ones are frequently the same business, and the market is now pricing Anthem as if the good half will keep outrunning the risky half.

Frequently asked questions

What does Anthem Biosciences actually do?

It is a CRDMO — a contract research, development and manufacturing organisation. Global pharma and biotech companies pay Anthem to discover, develop and manufacture the chemistry behind their drugs, from lab scale to commercial scale. It also sells fermentation-based specialty ingredients such as probiotics, enzymes and peptides.

When did Anthem Biosciences list, and how much did it raise?

It listed on the NSE and BSE on 21 July 2025 through a ₹3,395 crore IPO that was entirely an offer for sale, so the money went to selling shareholders rather than the company. The stock debuted at ₹723.05 on the NSE against a ₹570 issue price, a 26.85% premium.

How profitable is Anthem Biosciences?

Unusually so for the sector. In FY26 (year to March 2026) it reported revenue of ₹2,124 crore, profit after tax of ₹592 crore (up 31%), and an EBITDA margin of 43.4%. Operating margins have stayed in the high-30s to low-40s percent range for years.

Who founded Anthem Biosciences?

Ajay Bhardwaj, Dr Ganesh Sambasivam and K Ravindra Chandrappa founded it in 2006, with operations starting in Bengaluru in 2007. All three came from Biocon and its contract-research arm Syngene. Bhardwaj is Chairman and Managing Director.

What is the biggest risk for Anthem Biosciences?

Customer concentration: its top five customers made up 70.92% of FY25 revenue from operations. It also depends heavily on a single China-based supplier for materials and does not hedge its large foreign-currency revenue, per its IPO disclosures.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Screener.in — Anthem Biosciences consolidated financials (FY23–FY26 revenue, profit, margins, market cap), September 2026
• Whalesbook / Multibagg / ScanX — Anthem Biosciences FY26 and Q4 FY26 results (revenue ₹2,124 crore, PAT ₹592 crore, EBITDA margin 43.4%, net cash ₹1,375 crore), May 2026
• ICICI Direct — Anthem Biosciences IPO Note (price band, offer size, segment split, capacity), July 2025
• Aditya Birla Capital / stocksandsecurities — Anthem Biosciences IPO Note (risks, accreditations), July 2025
• India TV / Business Standard — Anthem Biosciences listing coverage (debut price, 26.85% premium, ₹40,716 crore market cap), July 2025
• TipRanks — Anthem Biosciences Q2 and H1 FY26 results, 2025
• True North — press note on Anthem Biosciences investment (stake and amount), March 2021
• Forbes — profile of Ajay Bhardwaj (founder background), June 2026
• Moneycontrol (via TradingView) — Anthem Biosciences on cost arbitrage and the China-alternative pitch, 2025
• Anthem Biosciences — corporate website (leadership, facilities, business overview)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.